Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This study planned to assess long-term safety and tolerability of QGE031 administered every 4 weeks for an additional 12 months in patients with allergic asthma who previously completed study CQGE031B2201. The study was terminated early due to the efficacy results from an interim analysis of the Phase II study CQGE031B2201.
Age
18–76
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
forced Expiratory Volume in one second ( FEV1) \>= 40% predicted
patients who completed CQGE031B2201 study
You may not be if
life-threatening asthma attack, intubation, respiratory arrest during or after completion of CQGE031B2201 study
new malignancy
ongoing SAE from CQGE031B2201 that was assessed as related to study drug
patient experienced platelets drop to \< 75,000/uL
patient experienced one unexpected grade 4 or two unexpected grade 3 hypersensitivity reactions
